397 related articles for article (PubMed ID: 26921922)
1. Role of the RANK/RANKL pathway in breast cancer.
Kiesel L; Kohl A
Maturitas; 2016 Apr; 86():10-6. PubMed ID: 26921922
[TBL] [Abstract][Full Text] [Related]
2. RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives.
Infante M; Fabi A; Cognetti F; Gorini S; Caprio M; Fabbri A
J Exp Clin Cancer Res; 2019 Jan; 38(1):12. PubMed ID: 30621730
[TBL] [Abstract][Full Text] [Related]
3. Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis.
Dougall WC
Clin Cancer Res; 2012 Jan; 18(2):326-35. PubMed ID: 22031096
[TBL] [Abstract][Full Text] [Related]
4. Can we prevent BRCA1-associated breast cancer by RANKL inhibition?
Kotsopoulos J; Singer C; Narod SA
Breast Cancer Res Treat; 2017 Jan; 161(1):11-16. PubMed ID: 27783278
[TBL] [Abstract][Full Text] [Related]
5. The anti-tumor effect of RANKL inhibition in malignant solid tumors - A systematic review.
de Groot AF; Appelman-Dijkstra NM; van der Burg SH; Kroep JR
Cancer Treat Rev; 2018 Jan; 62():18-28. PubMed ID: 29154022
[TBL] [Abstract][Full Text] [Related]
6. RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers.
Nolan E; Vaillant F; Branstetter D; Pal B; Giner G; Whitehead L; Lok SW; Mann GB; ; Rohrbach K; Huang LY; Soriano R; Smyth GK; Dougall WC; Visvader JE; Lindeman GJ
Nat Med; 2016 Aug; 22(8):933-9. PubMed ID: 27322743
[TBL] [Abstract][Full Text] [Related]
7. RANKL/RANK: from bone loss to the prevention of breast cancer.
Sigl V; Jones LP; Penninger JM
Open Biol; 2016 Nov; 6(11):. PubMed ID: 27881737
[TBL] [Abstract][Full Text] [Related]
8. Updates on the role of receptor activator of nuclear factor κB/receptor activator of nuclear factor κB ligand/osteoprotegerin pathway in breast cancer risk and treatment.
Bayer CM; Beckmann MW; Fasching PA
Curr Opin Obstet Gynecol; 2017 Feb; 29(1):4-11. PubMed ID: 28002265
[TBL] [Abstract][Full Text] [Related]
9. Denosumab for the treatment of bone metastases in advanced breast cancer.
Casas A; Llombart A; Martín M
Breast; 2013 Oct; 22(5):585-92. PubMed ID: 23759273
[TBL] [Abstract][Full Text] [Related]
10. Targeting RANKL in breast cancer: bone metastasis and beyond.
Azim H; Azim HA
Expert Rev Anticancer Ther; 2013 Feb; 13(2):195-201. PubMed ID: 23406560
[TBL] [Abstract][Full Text] [Related]
11. RANKL inhibition: a promising novel strategy for breast cancer treatment.
González-Suárez E
Clin Transl Oncol; 2011 Apr; 13(4):222-8. PubMed ID: 21493182
[TBL] [Abstract][Full Text] [Related]
12. BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells.
Cuyàs E; Corominas-Faja B; Martín MM; Martin-Castillo B; Lupu R; Brunet J; Bosch-Barrera J; Menendez JA
Oncotarget; 2017 May; 8(21):35019-35032. PubMed ID: 28388533
[TBL] [Abstract][Full Text] [Related]
13. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis.
Gonzalez-Suarez E; Jacob AP; Jones J; Miller R; Roudier-Meyer MP; Erwert R; Pinkas J; Branstetter D; Dougall WC
Nature; 2010 Nov; 468(7320):103-7. PubMed ID: 20881963
[TBL] [Abstract][Full Text] [Related]
14. RANK/RANKL signaling inhibition may improve the effectiveness of checkpoint blockade in cancer treatment.
van Dam PA; Verhoeven Y; Trinh XB; Wouters A; Lardon F; Prenen H; Smits E; Baldewijns M; Lammens M
Crit Rev Oncol Hematol; 2019 Jan; 133():85-91. PubMed ID: 30661662
[TBL] [Abstract][Full Text] [Related]
15. Progestogens and risk of breast cancer: a link between bone and breast?
González Ricarte M; de Castro Pérez A; Tarín JJ; Cano A
Gynecol Endocrinol; 2016; 32(1):6-8. PubMed ID: 26299383
[TBL] [Abstract][Full Text] [Related]
16. Denosumab: RANKL inhibition in the management of bone loss.
Hamdy NA
Drugs Today (Barc); 2008 Jan; 44(1):7-21. PubMed ID: 18301800
[TBL] [Abstract][Full Text] [Related]
17. Cell-based assay strategy for identification of motif-specific RANK signaling pathway inhibitors.
Chen T; Feng X
Assay Drug Dev Technol; 2006 Aug; 4(4):473-82. PubMed ID: 16945019
[TBL] [Abstract][Full Text] [Related]
18. Expression of receptor activator of nuclear factor kappa-B as a poor prognostic marker in breast cancer.
Park HS; Lee A; Chae BJ; Bae JS; Song BJ; Jung SS
J Surg Oncol; 2014 Dec; 110(7):807-12. PubMed ID: 25111682
[TBL] [Abstract][Full Text] [Related]
19. RANKL/RANK - from bone physiology to breast cancer.
Sigl V; Penninger JM
Cytokine Growth Factor Rev; 2014 Apr; 25(2):205-14. PubMed ID: 24486161
[TBL] [Abstract][Full Text] [Related]
20. The Roadmap of RANKL/RANK Pathway in Cancer.
Casimiro S; Vilhais G; Gomes I; Costa L
Cells; 2021 Aug; 10(8):. PubMed ID: 34440747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
